Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II study of EGT-101 for the treatment of Delayed Cerebral Ischemia (DCI) following aneurysmal subarachnoid hemorrhage

Next Previous
Trial Profile

A phase I/II study of EGT-101 for the treatment of Delayed Cerebral Ischemia (DCI) following aneurysmal subarachnoid hemorrhage

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 08 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EGT 101 (Primary)
  • Indications Ischaemia
  • Focus Adverse reactions

Most Recent Events

  • 08 Feb 2023 New trial record
  • 04 Feb 2023 According to an Egret Therapeutics media release, the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EGT 101. This trial is expected to begin enrolling patients in 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top